|
|
||||||||
INVITED REVIEWS
1New York University School of Medicine, New York; and 2Nephrology Section, New York Harbor Veterans Affairs Medical Center, New York, New York
Acetazolamide, a potent carbonic anhydrase (CA) inhibitor, is the most commonly used and best-studied agent for the amelioration of acute mountain sickness (AMS). The actual mechanisms by which acetazolamide reduces symptoms of AMS, however, remain unclear. Traditionally, acetazolamide's efficacy has been attributed to inhibition of CA in the kidneys, resulting in bicarbonaturia and metabolic acidosis. The result is offsetting hyperventilation-induced respiratory alkalosis and allowance of chemoreceptors to respond more fully to hypoxic stimuli at altitude. Studies performed on both animals and humans, however, have shown that this explanation is unsatisfactory and that the efficacy of acetazolamide in the context of AMS is likely due to a multitude of effects. This review summarizes the known systemic effects of acetazolamide and incorporates them into a model encompassing several factors that are likely to play a key role in the drug's efficacy. Such factors include not only metabolic acidosis resulting from renal CA inhibition but also improvements in ventilation from tissue respiratory acidosis, improvements in sleep quality from carotid body CA inhibition, and effects of diuresis.
carbonic anhydrase; altitude sickness; metabolic acidosis; hypercapnic ventilatory response; periodic breathing
This article has been cited by other articles:
![]() |
R. B. Schoene Illnesses at High Altitude Chest, August 1, 2008; 134(2): 402 - 416. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. C. Sun, J. Li, M. Cui, and J. A. Bonanno Role of Carbonic Anhydrase IV in Corneal Endothelial HCO3- Transport Invest. Ophthalmol. Vis. Sci., March 1, 2008; 49(3): 1048 - 1055. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |